Twist Bioscience Eyes Profit Turnaround In 2026 After Narrowing Losses
1. TWST reported a wider loss of 45 cents per share. 2. Sales increased 17% year-over-year, surpassing expectations. 3. Adjusted EBITDA loss narrowed significantly from last year. 4. Fiscal 2026 sales guidance is much higher than consensus. 5. Analysts see TWST as undervalued compared to peers.